Friday, July 28, 2017 4:13:42 PM
On July 24, 2017, Impax Laboratories, Inc. provided notice to DURECT that Impax is terminating the Asset Transfer and License Agreement dated January 3, 2014, which termination will be effective pursuant to the terms of such agreement on October 24, 2017. Termination returns to DURECT the development and commercialization rights to ELADUR ® (TRANSDUR ® -Bupivacaine). ELADUR is an investigational transdermal patch intended to deliver bupivacaine, a local analgesic. A summary of the material terms of the Impax Agreement was included in the Company’s Annual Report on Form 10-K filed on March 15, 2017, which is qualified in its entirety by reference to the full text of the Agreement (filed as Exhibit 10.75 to our Quarterly Report on Form 10-Q (File No. 000-31615) filed with the SEC on May 2, 2014 and incorporated by reference).
Recent DRRX News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/25/2024 03:24:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 01:00:08 PM
- DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 04:53:49 PM
- DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference • PR Newswire (US) • 09/04/2024 08:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:12 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2024 09:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:15:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/12/2024 08:10:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/12/2024 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 05:03:36 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/02/2024 08:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:35:08 PM
- DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis • PR Newswire (US) • 05/21/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:03:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:17:26 PM
- DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 05/13/2024 08:05:00 PM
- DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update • PR Newswire (US) • 05/07/2024 08:30:00 PM
- DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis • PR Newswire (US) • 04/30/2024 11:00:00 AM
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/27/2024 08:01:00 PM
- DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 03/20/2024 08:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM